AIM AIM ImmunoTech Inc.

$0.22▼ -2.29% Healthcare Other
After hours $0.22▼ -2.62% Sep 11, 7:45 PM ET
Volume 3.24M Avg Volume (10D) 22.99M
Key Metrics & Fundamentals
Market Cap
$7.87M
P/E Ratio
–
Div Yield
–%
52W Range
0.19 - 2.89
% vs 50 MA
-12.79%
% vs 200 MA
-67.71%
RSI-14
38.8
MACD Histogram
+0.0000
Beta (1Y vs SPY)
0.42
Free Cash Flow
-$2.75M
Gross Rev
$22,000
Gross Profit
$18,000
EBITDA
-$2.21M
COGS
$4,000
Operating Exp
$2.24M
Operating Income
-$2.23M
EBIT
-$2.23M
Pretax Income
-$3.02M
Net Income
-$3.02M
EPS (Diluted)
-0.69
Price & Volume History
Loading chart…
Recent News
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
GlobeNewswire · Sep 9, 2026 1:03 PM
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
GlobeNewswire · Sep 2, 2026 12:43 PM
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039
GlobeNewswire · Aug 31, 2026 12:51 PM
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
GlobeNewswire · Aug 27, 2026 1:01 PM
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article
GlobeNewswire · Aug 12, 2026 12:44 PM
AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point
GlobeNewswire · Aug 3, 2026 12:33 PM
Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical
Zacks · Jul 24, 2026 12:04 PM
Bet on 5 Top-Ranked Stocks With Rising P/E
Zacks · Jul 23, 2026 12:25 PM
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
GlobeNewswire · Jul 7, 2026 1:03 PM
AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
GlobeNewswire · Jun 24, 2026 12:29 PM
Financial Overview - Income Statement Quarterly

See AIM's money flow as a full page

Social Sentiment
Avg +0.56 · 64 posts
NewsBlue Origin Raising First Outside Capital, Seeking $10B at a $130B Valuation
r/StockMarket · Jul 8, 2026
positive +0.40
DiscussionNewsOracle power Plc
r/stocks · Jul 1, 2026
The post discusses the company's market listing and projects positively related to this listing.
positive +0.60
NewsDiscussionOuster hits all time high after AIM deal and robotics demand surge
r/stocks · Jun 29, 2026
The partnership is a positive development for both companies and the discussed application of Ouster’s sensors.
positive +0.60
DiscussionNvidia debuts RTX Spark processor for Windows laptops, taking aim at Intel, AMD
r/StockMarket · Jun 1, 2026
The post frames AMD as a competitor to RTX, suggesting a topic of interest within the broader semiconductor landscape.
positive +0.60
DiscussionNeed investment tracking app with TWR (Allinvestview?)
r/investing · May 11, 2026
The post is discussing a portfolio tracking app and the use of TWR, and refers to AllInvestview as the focus.
positive +0.60
Page 1 of 13 (64 total)
AI Analysis

Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙